Experience of the treatment of diabetic macular edema in patients with diabetes mellitus type II on the background of correction of lipid metabolism

2015 ◽  
pp. 169-177
Author(s):  
Nataliia Veselovska ◽  
Inna Zherebko ◽  
N. Kuchar
Keyword(s):  
Blood Serum ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Positive Trend ◽  
Type Ii ◽  
Intraocular Injection ◽  
Group I ◽  
Patients With Diabetes ◽  
Micronized Fenofibrate ◽  
Lipid Parameters

Problem. According to current observations, the increase in free cholesterol, low-density lipoprotein and triglyceride levels associated with the risk of diabetic macular edema (DME). Purpose. To study the effectiveness of pharmacological micronized fenofibrate, 145 mg in the complex treatment of patients with type II diabetes with diabetic macular edema. Material and methods. Two groups of patients with diabetes type II and DME were investigated. In the first group, patients received the fenofibrate, 145 mg during 8 months and onetime intraocular injection of aflіbersept; in the second one – only intraocular injection of aflіbersept. Assessment of the retina produced in all terms by visual acuity and retinal thickness of macular area with optical coherence tomography Stratus-3000 with control of the lipid parameters in blood serum. Results. In 8 months in group I, who obtained the drug fenofibrate, 145 mg, marked and more positive trend in ophthalmic and biochemical parameters and improve lipid profile were revealed. Conclusion. The paper presents the results of the comparative analysis to determine the effectiveness of micronized fenofibrate (Traykor®145 mg) in complex microsurgical treatment of DME with the control of the dynamics of changes in lipid parameters of blood serum was done.

scholarly journals Flavoprotein Fluorescence Correlation with Visual Acuity Response in Patients Receiving Anti-VEGF Injection for Diabetic Macular Edema

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Jorge S. Andrade Romo ◽  
Giselle Lynch ◽  
Kevin Liu ◽  
Daniel Kim ◽  
Michael Jansen ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Therapeutic Response ◽  
Diagnostic Methods ◽  
Fundus Photography ◽  
Additional Information ◽  
Structural Improvement ◽  
Anti Vegf ◽  
Patients With Diabetes

Anti-VEGF treatment of diabetic macular edema (DME) complicating diabetic retinopathy (DR) has greatly improved structural and visual outcomes for patients with diabetes mellitus. However, up to 50% of patients are either nonresponsive or refractory to anti-VEGF treatment (no improvement in BCVA or central macular thickness (CMT)). It is believed that factors such as mitochondrial structural and functional damage, due to oxidative stress, are partially responsible for this lack of improvement. Flavoprotein fluorescence (FPF) has been shown to be a sensitive marker of mitochondrial function and has been found to correlate with the degree of diabetic retinopathy. FPF may also provide additional information regarding therapeutic response of patients receiving anti-VEGF treatment for DME. Eight patients with DR and DME with clinically significant DME (CSDME) who underwent anti-VEGF (bevacizumab) treatment were imaged before injection and at follow-up visit using FPF in addition to standard color fundus photography and OCT CMT. A strong correlation r=0.98 (p=0.000015) between the FPF decrease and the BCVA improvement was observed; BCVA improved as FPF values decreased. Notably, in the same patients, the correlation between OCT CMT decrease and BCVA improvement (r=0.688) was not found to be significant (p=0.13). These findings suggest that FPF can detect improvement in metabolic function preceding structural improvement and even with small changes in edema. Additionally, FPF may be supplementary to current diagnostic methods for earlier detection of therapeutic response to anti-VEGF treatment in patients with DME.

Association between the Short-term Natural History of Diabetic Macular Edema and the Vitreomacular Relationship in Type II Diabetes Mellitus

Ophthalmology ◽  
1997 ◽  
Vol 104 (3) ◽  
pp. 473-478 ◽  
Author(s):  
Taiichi Hikichi ◽  
Naoki Fujio ◽  
Jun Akiba ◽  
Yoshinao Azuma ◽  
Masatoshi Takahashi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Natural History ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Type Ii Diabetes ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Short Term ◽  
History Of

scholarly journals Intraocular Risk Factors in the Primary Formation of Diabetic Macular Edema in Patients with Diabetes Mellitus Type II

2019 ◽  
Vol 16 (1) ◽  
pp. 63-69
Author(s):  
M. V. Pshenichnov ◽  
O. V. Kolenko ◽  
E. L. Sorokin ◽  
Yu. E. Pashentcev
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Comparison Group ◽  
Mean Value ◽  
Main Group ◽  
Type Ii ◽  
Diabetes Mellitus Type Ii ◽  
The Mean

Purpose. Revealing of the intraocular risk factors in the diabetic macular edema (ME) formatis in diabetes mellitus type II (DM2). Patients and methods. A 3.5-year research of 80 patients (160 eyes) with DM2 without signs of ME at the beginning of the research was performed. The main group consisted of 46 patients with ME symptoms on one or both eyes during the research period, the comparison group included 34 patients without ME symptoms to the end of the research. The initial ocular characteristics were retrospectively compared in groups.Results. The mean value of the axial lengths (AL) in the eyes of the main group was 23.12 ± 0.75 mm compared to 23.82 ± 0.62 mm in the comparison group (significant difference, p < 0.01). AL was less than 23.5 mm in 66 % eyes in the main group and only in 22 % of the eyes in the comparison group (p < 0.01). The mean value of the initial macular retina volume in the main group was significantly higher than in the comparison group — 7.51 ± 0.22 mm3 and 7.21 ± 0.12 mm3, respectively (p < 0.01). Initial background diabetic retinopathy (DR) was noted in 73 % eyes in the main group, which significantly differed from the comparison group, where this index was noted only in 13 % of the eyes (p < 0.01).Conclusion. Significant ocular risk factors for the formation of ME in patients with DM2 are: the initial macular retina volume more than 7.3 mm3, the value of the AL less than 23.5 mm; the initial background DR. The use of the detected morphometric parameters of eye and retina in combination with an adequate assessment of the risk factors in human organism makes it possible to assume a high risk of the primary formation of diabetic ME in patients with DM2 with high degree of probability.

scholarly journals Variability of diabetic macular edema in correlation with hypertension retinopathy in patients with diabetes mellitus and essential hypertension

2019 ◽  
Vol 63 (4) ◽  
pp. 327-338 ◽  
Author(s):  
Daniela Stana ◽  
Vasile Potop ◽  
Sînziana Luminiţa Istrate ◽  
Cecilia Eniceicu ◽  
Ana Raluca Mihalcea ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Essential Hypertension ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Patients With Diabetes

scholarly journals Pars Plana Vitrectomy versus Intravitreal Injection of Ranibizumab in the Treatment of Diabetic Macular Edema Associated with Vitreomacular Interface Abnormalities

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Hassan Elkayal ◽  
Ahmed M. Bedda ◽  
Hesham El-Goweini ◽  
Ahmed A. Souka ◽  
Amir Ramadan Gomaa
Keyword(s):  
Macular Edema ◽  
Intravitreal Injection ◽  
Diabetic Macular Edema ◽  
Pars Plana Vitrectomy ◽  
Vision Loss ◽  
Group I ◽  
Pars Plana ◽  
Vitreomacular Interface ◽  
The Mean ◽  
Group Ii

Purpose. To compare the efficacy of pars plana vitrectomy (PPV) versus intravitreal injection (IVI) of ranibizumab (RBZ) in the treatment of diabetic macular edema (DME) associated with vitreomacular interface abnormalities (VMIA). Methods. The records of patients presenting with DME and VMIA throughout 2016 to 2018 were retrospectively analyzed. The patients were divided into 2 groups: group I received IVIs of RBZ and group II underwent PPV with internal limiting membrane peeling. The main outcome measures were the change in the LogMAR corrected distance visual acuity (CDVA) and central subfield thickness (CSFT) on optical coherence tomography over 6 months. Results. At 6 months, mean CDVA improved by 0.22 ± 0.21 in group I patients p < 0.001 , while in group II, it improved only by 0.09 ± 0.22 p < 0.115 . Fifty-five percent of group I and 60% of group II patients had stable CDVA (within 2 lines from baseline) at 6 months. Significant improvement in vision (gain of 2 or more lines) was seen in 45% and 30%, respectively. Worsening of vision (loss of 2 or more lines) was seen only in 2 patients in group II, but none in group I. The mean CSFT improved significantly in both groups (by 162 µ and 216 µ, respectively; p < 0.001 ). The mean CSFT at 6 months was similar in both groups (354 µ and 311 µ, respectively; p = 0.172 ). Conclusions. Both treatments resulted in anatomical improvement of DME with concurrent VMIA. Visual improvement was more pronounced in the IVI group, although this may have been affected by other confounding factors.

Sign in / Sign up

Export Citation Format

Share Document